HOME >> MEDICINE >> NEWS
Study finds continued reduction in breast cancer incidence associated with longer use of raloxifene

Raloxifene (Evista) continues to be associated with more than a 50% reduction in breast cancer incidence beyond the first 4 years of treatment, according to a new study in the December 1 issue of the Journal of the National Cancer Institute.

The randomized, double-blind Multiple Outcomes of Raloxifene Evaluation (MORE) trial found that, in postmenopausal women with osteoporosis, 4 years of treatment with raloxifene was associated with a 72% reduction in breast cancer incidence compared with placebo. The Continuing Outcomes Relevant to Evista (CORE) trial was designed to examine the effect of an additional 4 years of treatment with raloxifene in the same group of women.

In the CORE trial, more than 4,000 women who had been part of the MORE trial continued taking either 60 mg/day of raloxifene, if they had been assigned to the raloxifene group in the MORE trial, or a placebo, if they had been assigned to the placebo group.

Silvana Martino, D.O., of the Cancer Institute Medical Group in Santa Monica, Calif., and colleagues report that, after the 4 years of the CORE trial, incidence of invasive breast cancer for women taking raloxifene was reduced by 59% compared with women taking the placebo, and incidence of estrogen-receptor (ER)-positive invasive breast cancer was reduced by 66%. Over the entire 8 years of MORE and CORE, the incidence of invasive breast cancer and ER-positive invasive breast cancer were reduced by 66% and 76%, respectively. There was no difference between the two groups in incidence of either ER-negative invasive breast cancer or noninvasive breast cancer. In both the MORE and CORE trials, there was a twofold increase in venous thromboembolic events, such as pulmonary embolism, among women taking raloxifene.

"[T]hese data demonstrate that the incidence of ER-positive invasive breast cancer continues to be reduced through 8 years of raloxifene treatment in postmenopausal women with osteoporosis," the authors w
'"/>

Contact: Sarah Zielinski or Kate Travis
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
30-Nov-2004


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2018)... ... December 06, 2018 , ... We ... life, there are alternative solutions. M.D.-formulated Relaxium Calm is a dietary supplement developed ... ingredient is Sensoril®, an extract of the ashwagandha root. Ashwagandha is a powerful ...
(Date:12/5/2018)... LIMEPORT, Pa. (PRWEB) , ... December 05, 2018 ... ... New Vitae Wellness and Recovery , has been reappointed to serve on ... on creating policies that support inclusion of those who identify with a cognitive ...
(Date:12/5/2018)... (PRWEB) , ... December 05, ... ... is advancing patient and family engagement with the use of the Precision ... reality technology provides Children’s National’s world-renowned neurosurgeons and physicians with a never-before ...
(Date:12/5/2018)... ... December 05, 2018 , ... Northeast Delta Human Services ... at North Monroe Baptist Church, 210 Finks Hideaway Rd, Monroe, LA 71203. , ... effort to educate and equip faith leaders to address substance abuse prevention, support ...
(Date:12/5/2018)... ... December 05, 2018 , ... What ... this condition are poorly understood. It manifests on the face, especially the cheeks, ... it can cause enormous social and psychological problems. , Although it is considered ...
Breaking Medicine News(10 mins):
(Date:12/6/2018)... ... December 06, 2018 , ... Today, the ... answers for the millions of Americans and people worldwide who suffer first-hand with ... the renowned Alternative to Meds Center utilizes the tenets of neurochemistry in assessing ...
(Date:12/5/2018)... ... ... Trivellini Tech announces the latest version of Trivellini system and it ... Nano, Trivellini Long Hair introduces the ability to harvest long hair grafts during FUE ... capabilities as the last generation but it can also be programmed to extract long ...
(Date:12/5/2018)... ... 04, 2018 , ... Florida Hospital West Florida Division has ... the prestigious Leapfrog Group, a national nonprofit health care ratings organization, announced the ... Center Sebring, Florida Hospital Wesley Chapel and Florida Hospital Zephyrhills all received the ...
Breaking Medicine Technology:
Cached News: